Chinese HPV vaccine in final stages of testing

22 July 2016

If approved, a human papilloma virus (HPV) vaccine currently in the final stages of clinical testing should be available in China within two years, the Chinese state news agency has reported.

Work on the cervical cancer vaccine began in 2002 and clinical tests started in 2011. The research is led by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases, based in Xiamen University in southeast China's Fujian Province.

It is the third HPV vaccine to reach the clinical test stage, following those developed by Merck and GlaxoSmithKline. The GSK vaccine was approved by the China Food and Drug Administration on Monday. Under the commercial name of Cervarix, it is the first HPV vaccine licensed for use in China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK